---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-106421"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:32:41.923329+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q3 revenue rises 15% to $44.2M; raises FY2025 guidance to $170-174M

## Summary
- Q3 continuing ops revenue $44.2M (+15% YoY); gross margin 48.2% vs 45.5%.
- Commercial Cell & Gene Therapy revenue up 36% YoY to $8.3M; supported 19 commercial therapies.
- GAAP net loss attributable to common stockholders $8.9M ($0.18 loss per share) in Q3.
- Adjusted EBITDA from continuing ops improved to -$0.6M from -$2.7M; cash/investments $421.3M.
- Full-year 2025 revenue guidance raised to $170M-$174M from continuing operations.

## SEC filing metadata
- accession: 0001104659-25-106421
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465925106421/0001104659-25-106421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465925106421/tm2530148d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-106421
- JSON: https://secwatch.observer/filing/0001104659-25-106421.json
- Plain text: https://secwatch.observer/filing/0001104659-25-106421.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.